KalVista Pharmaceuticals, Inc. announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE). The Innovation Passport is the first step in the UK?s Innovative Licensing and Access Pathway (ILAP), which is designed to accelerate a product?s time to market and facilitate patient access to innovative medicines. KalVista recently provided topline phase 3 data for sebetralstat, which displayed clinically and statistically significant results across all endpoints, and an excellent safety and tolerability profile.

The Company will be presenting late-breaking KONFIDENT trial data on February 25, 2024, at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.